Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
ST. LOUIS, March 02, 2018 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2017 financial results conference call | |
| When: | Tuesday, March 6th at 10:00 a.m. Eastern Time (7:00 a.m. PT) | |
| Dial In Number: | To access the live call, dial 877-627-6581 (US and Canada) or 719-325-4790 (International) and give the participant pass code 3267778. | |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com | |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Tuesday, March 13, 2018. To access the replay dial-in information, please click here. | |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
314-678-6100
[email protected]
